35 results about "Tensin" patented technology

An isolated sequence or peptide isolated from an E2, E4, E6, E7 early or late coding region of human papillomavirus (HPV) that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the E2, E4, E6, E7 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV. Also disclosed are isolated protein sequences or peptides from Harvey Ras (H-Ras), Kirsten Ras (K-Ras), and phosphatase and tensin homologue (PTEN) tumor suppressor proteins and Chlamydia trachomatis heat shock protein 60 (CHSP60 groEL1) and methods for detecting or diagnosing cancer or cellular abnormalities.

The invention is directed to methods of treating a solid tumor which expresses SALL4 and Phosphatase and Tensin Homolog (PTEN) in an individual in need thereof, comprising administering to the individual an effective amount of a composition that inhibits SALL4. In addition, the invention is directed methods of method of detecting an aggressive cancer in an individual in need thereof comprising detecting whether one or more cancer cells of the individual expresses SALL4, wherein if SALL4 is detected in the one or more cancer cells, then an aggressive cancer is detected in the individual, and methods of method of detecting a poor prognosis of a patient with cancer in an individual in need thereof, comprising detecting whether one or more cancer cells of the patient expresses SALL4, wherein if SALL4 is detected in the one or more cancer cells of the patient, then a poor prognosis is detected in the patient.

The invention belongs to the field of biomedicine, and particularly relates to an up-stream open reading frame (uORF) of a phosphatase and tensin homolog (PTEN) gene, and applications of a protein encoded by the uORF. According to the present invention, the 5'UTR of PTEN has a potential 138-base open reading frame (45aa-uORF), wherein the 138-base open reading frame can encode a short peptide having 45 amino acids (named PTEN-45aa), and the short peptide has important effects in the occurrence and development process of tumors; and the new diagnosis, the new treatment method and the new drug screening platform are provided for diseases associated with PTEN expression regulation, particularly gliomas. The invention further provides a polypeptide for treating diseases associated with PTEN expression regulation.

The invention relates to the field of gene engineering and concretely relates to an anti-tumor phosphatase and tensin homolog deleted on chromosome ten (PTEN)-VP22 gene. The anti-tumor PTEN-VP22 gene comprises a nucleotide sequence (i) shown in the formula SEQ ID NO.1 in the sequence table or comprises a nucleotide sequence (ii) having homology of 95% with the nucleotide sequence (i). A protein coded by the anti-tumor PTEN-VP22 gene can effectively inhibit tumor cells, can effectively penetrate a cell membrane thereby producing inhibition effects on tumor cells and has active effects in PTEN gene clinical application.

The invention discloses a face beautifying method. The face beautifying method comprises the following steps that 1, conventional face cleaning is carried out to meet aseptic requirements; 2, preoperative anesthesia is carried out; 3, ultra-fine plant fibers serve as a carrier, and skin-tendering essence is guided into skin cells through an instrument at a special wave frequency. According to themethod, sodium hyaluronate and collagen which are essential to the human body are diluted with normal saline and then directly injected into subcutaneous tissue in a certain proportion to stimulate generation of tensin and enhance extracellular mesenchymal tissue, so that the skin comprehensively recovers the specific elasticity and luster in youth, the supplementary repair is completely derived from the self repair and regeneration capability of the skin, a good face lifting effect of facelifts and the like and a continuous tightening effect of collagen hyperplasia are completely retained, damage of surgical instruments to blood vessels and subcutaneous tissue of the human body is abandoned, and incision scars and the sequela of a hair-free region are avoided. The method has the advantages that general anesthesia is not needed, the recovery period is short, and complications and side effects are avoided.

The invention discloses a research method for the pharmacologic action of mangiferin on mouse diabetes. The research method comprises material selection and an experimental method, biochemical parameter evaluation, histological analysis, measurement of reactive oxygen species (ROS), determination of malondialdehyde (MDA) and antioxidase, analysis of renal tissue inflammatory factors, immunofluorescent staining, Western blotting and statistic analysis. According to the research method, a trichrome staining method is utilized to observe renal morphology; a kit is utilized to determine a blood biochemical index; levels of inflammatory cytokines, the antioxidase, the MDA and the ROS are determined; expression of fibronectin, collagen I and alpha-SMA is detected by an immunohistochemical method, and regulation of paths of TGF-beta 1 and phosphatase and tensin homolog / phosphatidylinositol 3-hydroxy kinase / protein kinase B (PTEN / PI3K / Akt) is detected by Western blotting; researches show thatthe mangiferin can significantly improve the renal dysfunction of diabetic mice; renal interstitial fibrosis can be prevented by reducing positive expression of fibronectin (FN), collagen type I (ColI) and alpha-smooth muscle actin (SMA) during therapy with the mangiferin; and meanwhile, mangiferin increases the antioxidase, reduces phosphorylation of the PI3K and Akt, inhibits the renal interstitial fibrosis, and provides more theoretical foundations for clinical application of traditional Chinese medicine in treating diabetes.

The invention relates to the field of biotechnology, in particular to a novel application of MicroRNA (micro ribonucleic acid) 221-3p to promotion of epidermal cell proliferation, and provides an application of MicroRNA 221-3p to preparation of a reagent for promoting epidermal cell proliferation. The reagent comprises but is not limited to MicroRNA 221-3p, a recombinant vector containing a MicroRNA 221-3p coding gene, a recombinant virus containing the MicroRNA 221-3p coding gene, and a recombinant virus vector containing the MicroRNA 221-3p coding gene. The experiment proves that MicroRNA 221-3p can inhibit expression of PTEN (phosphatase and tensin homolog deleted on chromosome ten) and remarkably increase epidermal cell proliferation speed, and the characteristics of epidermal cells are not lost; MicroRNA 221-3p relates to epidermal cell proliferation. The invention provides novel thought and mode for quickly proliferating the epidermal cells and quickly obtaining tissue engineering skin.

The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphataseand tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.

Described are methods of treating a solid tumor which expresses Spalt-Like Transcription Factor 4 (SALL4) and Phosphatase and Tensin Homolog (PTEN) in an individual in need thereof, comprising administering to the individual an effective amount of a composition that inhibits SALL4. In addition, the invention is directed to methods of detecting an aggressive cancer in an individual in need thereof as well as methods of detecting a poor prognosis of a patient with cancer in an individual in need thereof.

The invention provides oligonucleotide and a method for joint detection of relative transcript levels of genes PTEN (phosphatase and tensin homolog deleted on chromosome ten) and VEGF (vascular endothelial cell growth factor) based on fluorogenic quantitative PCR (Polymerase Chain Reaction), mainly relating to a forward primer PTEN-F, a reverse primer PTEN-R and a probe PTEN-Probe for detecting the gene PTEN; an forward primer VEGF-F, a reverse primer VEGF-R and a probe VEGF-Probe for detecting the gene VEGF; and a forward primer Actin-F, a reverse primer Actin-R and a probe Actin-Probe for detecting a reference gene actin. The relative transcript levels of the detected genes PTEN and VEGF are respectively compared with reference values of the relative transcript levels of the genes PTEN and VEGF of a healthy person, and the comparison result can be used for auxiliary diagnosis of various kinds of cancers.

The present invention relates to a pharmaceutical composition for preventing and treating cancer, cancer metastasis and bone metabolic diseases, which comprises FSTL1 (Follistatin-like 1) protein as an active ingredient. More specifically, FSTL1 inhibits AKT activity and increases activity of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome 10), while inhibiting DNA binding of NF-κB (nuclear factor-κB) and blocking the expression of target genes IL-6, GM-CSF, MMP-9, VEGF and ICAM1, and exhibits significant inhibitory effects on breast cancer growth and metastasis in animal models. Therefore, it can be useful for inhibiting cancer metastasis including breast cancer.

The invention belongs to the field of tumor drugs and discloses an application of oroxylin A in preparation of an inhibitor with a targeting effect on AFP (alpha fetoprotein) of hepatoma cells. The technical scheme is the application of oroxylin A in preparation of the inhibitor with the targeting effect on AFP of the hepatoma cells. The application proves that oroxylin A can have the targeting effect on a clinical diagnostic mark AFP of hepatoma, can down-regulate protein level of AFP, is directly bound with AFP, inhibits bonding of AFP and tumor suppressor protein PTEN (phosphatase and tensin homolog), has effects of inhibiting proliferation of the hepatoma cells and inducing apoptosis of the hepatoma cells, and has better clinical value.

The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1. The pharmaceutical composition according to the present invention, which is for preventing or treating diabetes or a complication of diabetes and comprises the TENC1 expression or activity suppressor as an active ingredient, can be expected to be widely usable in preventing and treating diabetes or a complication of diabetes since the pharmaceutical composition can effectively prevent the muscular dystrophy and reduction in sugar adsorption that occur due to reduction in IRS-1 by suppressing degradation of IRS-1 caused by TENC1.

The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

The invention relates to a PTEN (phosphatase and tensin homolog) gene interference shRNA3 of which the nucleotide sequence is shown in SEQ ID No.1. The invention also provides a recombinant adenovirus vector containing the PTEN gene interference shRNA3 as well as a construction method and application thereof. According to the invention, by selecting an RNAi (RNA interfere) technology, a pAdxsi-GFP-PTEN-shRNA vector is successfully constructed, and through culturing and amplifying, an interference recombinant adenovirus with a titer of 1.2*10<10> PFU (Plaque Forming Unit) / ml is obtained, so that the expression of PTEN genes can be reduced, and due to the low expression of PTEN, the assembling and secretion of VLDL (very low-density lipoprotein) are reduced, and then the accumulation of intracellular TG is caused, thereby promoting accumulation of fats in liver cells.

The invention provides a method for detecting a PTEN gene and a PI3K (Phosphatidyl Inositol 3-kinase) / AKT (Protein Kinase B) protein and an application of the method in breast cancer individuation treatment. The method is characterized in that a DNA (deoxyribonucleic Acid) sequencing method is used for detecting the PTEN in pathological tissues of breast cancer patients, a WesternBlot technology is used for detecting the expression condition of the PI3K / AKT protein, and detection results are accurate and reliable. The detection method provided by the invention can be used for accurately judging the tolerance of patients to trastuzumab in combination with the sensitivity of the breast cancer patients to the trastuzumab, providing the basis for the diagnosis, treatment and evaluation of the breast cancer patients and preventing the trastuzumab (Herceptin) from being blindly used to cause the missing of treatment opportunity and the economic loss for the patients.

The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1. The pharmaceutical composition according to the present invention, which is for preventing or treating diabetes or a complication of diabetes and comprises the TENC1 expression or activity suppressor as an active ingredient, can be expected to be widely usable in preventing and treating diabetes or a complication of diabetes since the pharmaceutical composition can effectively prevent the muscular dystrophy and reduction in sugar adsorption that occur due to reduction in IRS-1 by suppressing degradation of IRS-1 caused by TENC1.

Provided are an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a protein coded by the uORF. A potential ORF of 138 bases (45aa-uORF) in the 5′UTR of the PTEN, coding an oligopeptide of 45 amino acids (named PTEN-45aa) plays an important role in the development and progression progress of tumors. Further provided are a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular neuroglioma. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.

A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), referred to as Treg resistance. The method includes measuring the expression levels of phosphatase and tension homolog (PTEN) in activated CD4+ T-cells. Furthermore, a screening method for the detection of an autoimmune disease or a condition, may comprise the steps of generating a functional gene expression profile by measuring the expression levels of phosphatase and tension homolog (PTEN) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls. PTEN can be utilized in a screening system for the detection of impaired responsiveness of CD4+ T-cells to Treg.

The present application discloses a method of growing or proliferating nerve cells by contacting the cells with phosphatase and tensin homolog (PTEN) lipid phosphatase inhibiting peptide.

The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.

Provided are an oncolytic virus for treating brain tumors using a recombinant Newcastle disease virus into which a Newcastle disease virus (NDV) vector-based PTEN (phosphatase and tensin homolog) gene is inserted and a composition for treating brain tumors using the same which can be used for a therapeutic viral agent that can induce reduction of clinical symptoms or partial or complete remission through brain tumor cell death or brain tumor tissue reduction by expressing normal PTEN protein after being infected with brain tumor cells, as a recombinant Newcastle disease virus containing a human PTEN protein gene.

The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well.

Provided are applications of an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a polypeptide coded by the same. A potential ORF of 96 bases (31aa-uORF) existing in the 5′ UTR of the PTEN can code an oligopeptide of 31 amino acids (named PTEN-31aa) and plays an important role in the development and progression process of tumors. Provided is a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular gliomas. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.

Provided is a pharmaceutical composition for preventing or treating diabetic nephropathy, comprising a tensin like C1 domain containing phosphatase (TENC1) inhibitor as an active ingredient. A new target for treating diabetic nephropathy is presented by confirming that TENC1 expression is increased in kidney tissue of diabetes or a podocyte cell line to which a high blood glucose environment is given and experimentally proving that nephrin phosphorylation inhibited by the PTPase activity of TENC1 affects the permeability and mTORC1 signaling of the podocytes resulting in inducing podocyte hypertrophy. As the pharmaceutical composition comprising a TENC1 inhibitor as an active ingredient inhibits nephrin dephosphorylation by TENC1, podocytes damaged from an early stage of the diabetic nephropathy may be protected and the structure and filtration function of the podocytes may be maintained, therefore the pharmaceutical composition is expected to be widely used in preventing or treating the diabetic nephropathy from an early stage.

The invention relates to a construction method for a LN-229 cell line with low expression of phosphatase and tensin homolog (PTEN). The stable LN-229 cell line with low expression of PTEN is constructed by utilizing a lentivirus system; shPTEN and lentivirus packaging plasmids are transfected into HEK293T cells; a virus supernatant is collected to infect LN-229 cells; the transfected LN-229 cellsare screened with puromycin to obtain the stable LN-229 cell line with low expression of PTEN; and finally, tested by a Western blot technique, the expression of PTEN of cell strains is decreased by more than 80%, and thus, the cell line with low expression of PTEN is successfully constructed. The cell line can serve as an ideal cell line for researching the molecular action mechanism and the participating metabolic regulation effect of PTEN in glioma.